Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05417594 · ClinicalTrials.gov registry record · Phase 1
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
A Phase 1 study of Advanced Solid Malignancies, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 695
- Enrollment target
- 20
- Study locations
NCT05417594: Recruiting Phase 1 study of Advanced Solid Malignancies, sponsored by AstraZeneca.
NCT05417594 is a Phase 1 study of Advanced Solid Malignancies that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 695 participants, above the 130-participant average among 6 other Advanced Solid Malignancies trials with a reported enrollment target (435% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05417594, a Phase 1 study of Advanced Solid Malignancies, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 695 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.
Primary Outcome
The safety and tolerability of AZD9574 as monotherapy and in combination with anti-cancer agents and TMZ in participants with advanced malignancies will be assessed.
Conditions Studied
Interventions
- DRUG AZD9574
- DRUG Trastuzumab Deruxtecan (T-DXd)
- DRUG Temozolomide (TMZ)
- DRUG [11C]AZ1419 3391
- DRUG Datopotamab Deruxtecan (Dato-DXd)
Study Locations (20)
Other
- Research Site - Camperdown
- Research Site - Darlinghurst
- Research Site - Melbourne
- Research Site - Randwick
- Research Site - Bayern
- Research Site - Berlin
- Research Site - Heidelberg
- Research Site - Mainz
- Research Site - Seoul
California
- Research Site - La Jolla
- Research Site - Los Angeles
- Research Site - San Francisco
New York
- Research Site - New York
- Research Site - New York
Texas
- Research Site - Houston
- Research Site - San Antonio
Illinois
- Research Site - Chicago
Massachusetts
- Research Site - Boston
Oregon
- Research Site - Portland
Virginia
- Research Site - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 695 participants |
| Start Date | 2022-06-24 |
| Est. Completion | 2027-08-11 |
| Phase | Phase 1 |
What NCT05417594 shows while recruiting
NCT05417594 is an interventional study that assigns participants to a tested intervention. The registered 695 participants enrollment target is mid-sized for trials with a published cap, above the 130-participant average among 6 other Advanced Solid Malignancies trials with a reported enrollment target (435% higher).
The record links to 1 condition, with Advanced Solid Malignancies appearing as the primary indexed condition, and to 5 interventions - of which AZD9574 is the first listed.
NCT05417594 names 20 study sites across 8 states, led by Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT05417594 about?
NCT05417594 is a clinical study titled "Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies". This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.
What is the current status of trial NCT05417594?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 695 participants. The study started on 2022-06-24. Estimated completion is 2027-08-11.
What conditions does trial NCT05417594 study?
This clinical trial studies the following conditions: Advanced Solid Malignancies.
What interventions are being tested in trial NCT05417594?
The interventions under investigation include: AZD9574 (DRUG), Trastuzumab Deruxtecan (T-DXd) (DRUG), Temozolomide (TMZ) (DRUG), [11C]AZ1419 3391 (DRUG), Datopotamab Deruxtecan (Dato-DXd) (DRUG).
Who is sponsoring clinical trial NCT05417594?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05417594 being conducted?
This trial has 20 study locations across California, Illinois, Massachusetts, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
ACTIVE NOT RECRUITING · Phase 1
-
Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06801834 · 695 participants · Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- NCT07179016 · 693 participants · NA
Evaluating the Auricular Point Acupressure-Self Management Program for Chronic Musculoskeletal Pain Among Rural Populations
- NCT03136094 · 698 participants · NA
Suicide in Urban Natives: Detection and Networks to Combat Events
- NCT04928846 · 698 participants · Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI